{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-006284","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.027110+00:00","generated_at":"2026-05-30T01:57:58.148136+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Corvus Q3 net loss $40.2M; soquelitinib atopic dermatitis interim data due Dec 2024","bullets":["Net loss of $40.2M for Q3 2024, including $32.8M non-cash warrant liability loss, vs $6.0M loss in Q3 2023.","Cash, equivalents and marketable securities $41.7M at Sep 30, 2024; projected year-end cash $38-39M.","October 2024 early warrant exercise raised $5.9M; approx. 15.4M warrants outstanding expiring June 2025.","Soquelitinib Phase 1 atopic dermatitis trial second cohort (200mg QD) enrolling; interim data expected Dec 2024.","Soquelitinib Phase 3 PTCL registrational trial enrolling at multiple sites; Orphan Drug and Fast Track granted."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-006284","json":"https://secwatch.observer/filing/0001171843-24-006284.json","markdown":"https://secwatch.observer/filing/0001171843-24-006284.md","text":"https://secwatch.observer/filing/0001171843-24-006284.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000117184324006284/0001171843-24-006284-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000117184324006284/f8k_111224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:57:58.148136+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}